Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Female Contraception - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H2 2016, provides an overview of the Female Contraception (Women's Health) pipeline landscape. Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones). Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 5, 2, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively. Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health). - The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Female Contraception Overview 9 Therapeutics Development 10 Pipeline Products for Female Contraception - Overview 10 Pipeline Products for Female Contraception - Comparative Analysis 11 Female Contraception - Therapeutics under Development by Companies 12 Female Contraception - Therapeutics under Investigation by Universities/Institutes 13 Female Contraception - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Female Contraception - Products under Development by Companies 17 Female Contraception - Products under Investigation by Universities/Institutes 19 Female Contraception - Companies Involved in Therapeutics Development 20 Addex Therapeutics Ltd 20 Agile Therapeutics Inc 21 ANI Pharmaceuticals Inc 22 Bayer AG 23 Evofem Inc 24 Hervana Ltd 25 Mithra Pharmaceuticals SA 26 Orbis Biosciences Inc 27 Teva Pharmaceutical Industries Ltd 28 Viramal Ltd 29 Female Contraception - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 (anastrozole + levonorgestrel) - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 (drospirenone + estetrol) - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 (estradiol acetate + prasterone + progesterone) - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 (estradiol acetate + segesterone acetate) - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ADX-68693 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 AG-200 ER - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AG-200 SP - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AG-20015 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 AG-890 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Amphora - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 BAY-1007626 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 drospirenone - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Drug for Female Contraception - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 EC-508 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Estetrol - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 etonogestrel ER - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 EVE-106 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 LJ-102 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Monoclonal Antibody Conjugates for Female Contraception - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 NOV-1003 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 S-003296 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 S-0101255 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Small Molecule 2 for Fertility Control - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Small Molecule for Female Contraception - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Small Molecule to Target Progesterone Receptor for Fertility Control - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Synthetic Peptides for Female Contraception - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 TV-46046 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Female Contraception - Dormant Projects 77 Female Contraception - Discontinued Products 79 Female Contraception - Product Development Milestones 80 Featured News & Press Releases 80 Nov 07, 2016: Agile Therapeutics Announces Completion of Subject Visits for Twirla Phase 3 SECURE Clinical Trial 80 Sep 23, 2016: Mithra Pharmaceuticals: Phase III Clinical Study for Estelle in US Launched with first Randomized Patient 80 Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68693 80 Jul 22, 2016: Green Light From FDA For The Launch Of Estelle (E4/Drsp) Phase III Study In The United States 81 Jul 20, 2016: Canada Approves Clinical Trial Application For Estelle (E4/DRSP) PhasePhase III Study 82 Jul 12, 2016: Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline 82 Jun 30, 2016: First Patient Screened For The European Product Candidate Estelle (E4/Drsp) Phase III Clinical Study 83 Jun 16, 2016: Agile Therapeutics Announces Issuance of Patent for Progestin Patch Designs 83 Apr 05, 2016: FDA Feedback On Spa Estelle: A New Step Closer To The Launch Of Estelle Phase III Pivotal Clinical Studies 83 Apr 01, 2016: Topline Results Of Food Effect Study Of The Product Candidate Estelle, The New Combined Oral Contraceptive Composed Of 15 mg Of Estetrol (E4) And 3 mg Of Drospirenone 84 Mar 24, 2016: Already 4 European Countries Fully Approved Protocol Of MIT-ES001-C301 Estelle Phase III Clinical Study 84 Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial 85 Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial 85 Sep 22, 2015: Evofem Announces FDA Acceptance of New Drug Application for Amphora as a Contraceptive 86 Aug 31, 2015: Agile Therapeutics Announces Completion of Patient Recruitment in Twirla Phase 3 SECURE Clinical Trial 86 Appendix 88 Methodology 88 Coverage 88 Secondary Research 88 Primary Research 88 Expert Panel Validation 88 Contact Us 88 Disclaimer 89
List of Tables
Number of Products under Development for Female Contraception, H2 2016 10 Number of Products under Development for Female Contraception - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Products under Investigation by Universities/Institutes, H2 2016 19 Female Contraception - Pipeline by Addex Therapeutics Ltd, H2 2016 20 Female Contraception - Pipeline by Agile Therapeutics Inc, H2 2016 21 Female Contraception - Pipeline by ANI Pharmaceuticals Inc, H2 2016 22 Female Contraception - Pipeline by Bayer AG, H2 2016 23 Female Contraception - Pipeline by Evofem Inc, H2 2016 24 Female Contraception - Pipeline by Hervana Ltd, H2 2016 25 Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H2 2016 26 Female Contraception - Pipeline by Orbis Biosciences Inc, H2 2016 27 Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 28 Female Contraception - Pipeline by Viramal Ltd, H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Assessment by Combination Products, H2 2016 31 Number of Products by Stage and Target, H2 2016 33 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 39 Female Contraception - Dormant Projects, H2 2016 77 Female Contraception - Dormant Projects (Contd..1), H2 2016 78 Female Contraception - Discontinued Products, H2 2016 79
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
